<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2361">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05130424</url>
  </required_header>
  <id_info>
    <org_study_id>HNHQRWS</org_study_id>
    <nct_id>NCT05130424</nct_id>
  </id_info>
  <brief_title>A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province</brief_title>
  <official_title>A Real-world Study of Herombopag in the Treatment of Thrombocytopenia Related Diseases in Henan Province</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SuxiaLuo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To observe and evaluate the safety and effectiveness of herombopag in the treatment of&#xD;
      thrombocytopenia-related diseases in Henan Province&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a real-world study on the treatment of thrombocytopenia-related&#xD;
      diseases with Herombopag, to observe and analyze the safety and efficacy of Herombopag for&#xD;
      thrombocytopenia-related diseases in the real world.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events after the treatment of Herombopag</measure>
    <time_frame>From the treatment of Herombopag to 28 days after the end of the medication</time_frame>
    <description>The investigator will observe incidence of adverse events after the treatment of Herombopag, including thrombosis, diarrhea, abnormal liver function and so on.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of the platelet counts after the treatment of Herombopag</measure>
    <time_frame>From the treatment of Herombopag to 28 days after the end of the medication</time_frame>
    <description>The investigator will assess the changes of the platelet counts after the treatment of Herombopag。</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with platelet transfusion</measure>
    <time_frame>From the treatment of Herombopag to 28 days after the end of the medication</time_frame>
    <description>The investigator will assess the proportion of patients with platelet transfusion after the treatment of Herombopag。</description>
  </secondary_outcome>
  <enrollment type="Anticipated">498</enrollment>
  <condition>Carcinoma;Blood</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Herombopag</intervention_name>
    <description>Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with thrombocytopenia-related diseases&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Thrombocytopenia related diseases;&#xD;
&#xD;
          2. Volunteer to join this study and sign an informed consent form;&#xD;
&#xD;
          3. Clinical evaluation can benefit from Herombopag.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those who have been confirmed to be allergic to Herombopag and/or its excipients;&#xD;
&#xD;
          2. Pregnant or breastfeeding women;&#xD;
&#xD;
          3. Except for patients with contraindications to Herombopag;&#xD;
&#xD;
          4. Doctors evaluate patients who are not suitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>suxia luo</last_name>
    <phone>18638553211</phone>
    <email>luosxrm@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>wenying deng</last_name>
    <phone>15837168169</phone>
    <email>psc1969@sohu.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suxia Luo, Doctor</last_name>
      <phone>0371-65587697</phone>
      <email>2290773710@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Henan Cancer Hospital</investigator_affiliation>
    <investigator_full_name>SuxiaLuo</investigator_full_name>
    <investigator_title>chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

